Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

0.3238 -0.0012 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 860,447
Open 0.3200
Bid (Size) 0.3100 (10)
Ask (Size) 0.3280 (39)
Prev. Close 0.3250
Today's Range 0.3065 - 0.3285
52wk Range 0.2603 - 11.26
Shares Outstanding 55,185,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

YTD
-96.89%
-96.89%
1 Month
-13.31%
-13.31%
3 Month
-77.97%
-77.97%
6 Month
-78.41%
-78.41%
1 Year
-94.86%
-94.86%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Via Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
Via Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
From Marinus Pharmaceuticals
Via Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Via MarketBeat
Topics ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Via MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
3 Biotech Stocks to Sell in August Before They Crash & Burn
Via InvestorPlace
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
From The Law Offices of Frank R. Cruz
Via Business Wire
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.